We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Persistent Urinary Albumin May Indicate Risk for Cognitive Decline in Type II Diabetics

By LabMedica International staff writers
Posted on 10 Sep 2013
The chronic presence of albumin in the urine (albuminuria) of individuals with type II diabetes has been linked to a gradual decline in their ability to process information (i.e., cognitive decline).

Investigators at Kaiser Permanente of Georgia/Emory School of Medicine (Duluth, GA, USA) determined the level of albumin in urine samples obtained from participants in the Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study. More...
This study comprised 2,977 individuals with mean age 62.5 years who had been recruited from August 2003 to December 2005 and then followed through June 2009. The purpose of the study was to examine the association of intensive versus standard glucose control on cognitive function. Participants underwent three neuropsychologic tests at baseline, 20 months, and 40 months. Tests included information processing speed, verbal memory, and executive function. Urine albumin measurements were carried out in parallel with the memory tests.

Results revealed that participants with albuminuria at baseline and follow-up (persistent albuminuria) and participants with albuminuria at follow-up but none at baseline (progressive albuminuria) had greater percentage declines on information processing speed than participants without albuminuria at baseline and at follow-up (no albuminuria). Persistent albuminuria and progressive albuminuria were associated with about a 5% decline in information processing speed scores but not with verbal memory or executive function performance.

Senior author Dr. Joshua Barzilay, an endocrinologist at Kaiser Permanente, said, “Our finding was a subtle change in cognition; however, were this decline to continue over 10 to 15 years it could translate into noticeable cognitive decline by the age of 75 to 80 years, when cognitive impairment generally becomes clinically evident. Given how common albuminuria and diabetes are in the older population, these findings have a great deal of importance from a population point of view. Moreover, albuminuria is also common among older people with hypertension without diabetes.”

The study was published in the August 29, 2013, online edition of the Clinical Journal of the American Society of Nephrology.

Related Links:

Kaiser Permanente of Georgia/Emory School of Medicine



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.